Additional steps towards the commercialization of Ygalo®
Stockholm - 5 November 2018 - Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today the notice for an Extraordinary General Meeting in which the Nomination Committee is proposing one new candidate for the Board of Directors. Over the last few years, Oncopeptides has taken its lead compound closer to market and is currently conducting pivotal trials with melflufen (Ygalo®). The company continues to prepare for stand-alone commercialisation in the US and Europe. As part of these activities, the Nomination Committee has worked to strengthen the profile of the Board of Directors with regard